RxDoctor Payments Data

Shern Sirisuk, DO

Family Medicine · Riverside, CANPI 1083699375

Payments from drug & device makers

$481in general payments, 2019–2025

Across 20 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$144
  • Abbott$128
  • GSK$72
  • Novo Nordisk$65
  • Boehringer Ingelheim$27
  • Xeris Pharmaceuticals, Inc.$18
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$481 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$46,553
Medicare patients
148
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide199$220,079
JardianceEmpagliflozin146$153,142
EliquisApixaban132$124,032
XareltoRivaroxaban49$65,305
TrulicityDulaglutide37$49,352
FarxigaDapagliflozin Propanediol36$27,552
MounjaroTirzepatide25$24,886
JanuviaSitagliptin Phosphate24$23,675
MyrbetriqMirabegron32$21,496
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$17,818
Bydureon BciseExenatide Microspheres12$16,403
OxycontinOxycodone Hcl14$12,552
LyricaPregabalin14$12,172
Spiriva RespimatTiotropium Bromide15$10,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$220,079199 claims
Boehringer IngelheimJardiance, Spiriva Respimat$27$163,654161 claims
Lilly USA, LLCTrulicity, Mounjaro$12$74,23962 claims
GSKAnoro Ellipta, Trelegy Ellipta$72$27,58833 claims
AstraZenecaFarxiga$144$27,55236 claims
MerckJanuvia$15$23,67524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →